For the year ending 2025-12-31, HCAT had -$198,831K decrease in cash & cash equivalents over the period. -$237K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -177,974 |
| Stock-based compensation expense | 27,012 |
| Depreciation and amortization | 50,500 |
| Investment discount and premium accretion | 1,565 |
| Impairment of long-lived assets | 6,900 |
| Non-cash operating lease expense | -2,930 |
| Provision for expected credit losses | 1,503 |
| Amortization of debt discount, issuance costs, and deferred financing costs | 3,725 |
| Deferred tax provision | 81 |
| Change in fair value of contingent consideration liabilities | -7,063 |
| Impairment of goodwill and intangible assets | 110,223 |
| Other | -429 |
| Accounts receivable, net | 1,809 |
| Prepaid expenses and other assets | -1,569 |
| Accounts payable, accrued liabilities, and other liabilities | -11,512 |
| Deferred revenue | 607 |
| Operating lease liabilities | -3,967 |
| Net cash provided by (used in) operating activities | 731 |
| Proceeds from the sale and maturity of short-term investments | 163,948 |
| Purchases of short-term investments | 65,132 |
| Capitalization of internal-use software | 19,780 |
| Acquisition of businesses, net of cash acquired | 41,114 |
| Purchases of property and equipment | 968 |
| Purchases of intangible assets | 805 |
| Proceeds from the sale of property and equipment | 44 |
| Net cash provided by (used in) investing activities | 36,193 |
| Proceeds from issuance of long-term debt, net of issuance costs | 0 |
| Payment of deferred financing costs | 0 |
| Repayment of debt | 232,292 |
| Proceeds from employee stock purchase plan | 1,510 |
| Proceeds from exercise of stock options | 0 |
| Repurchase of common stock | 5,000 |
| Net cash (used in) provided by financing activities | -235,782 |
| Effect of exchange rate changes on cash and cash equivalents | 27 |
| Net (decrease) increase in cash and cash equivalents | -198,831 |
| Cash and cash equivalents at beginning of period | 249,645 |
| Cash and cash equivalents at end of period | 50,814 |
Health Catalyst, Inc. (HCAT)
Health Catalyst, Inc. (HCAT)